Is there an “amlodipine free base” product, or only amlodipine besylate?
Amlodipine is most commonly marketed as a salt—especially amlodipine besylate—rather than as a standalone “free base” form. Many drug products specify the active ingredient as amlodipine besylate in their labeling, which makes “free base” formulations less common in day-to-day availability and prescribing.
What formulations of amlodipine are typically available?
In practice, commercially available amlodipine products are usually:
- Immediate-release tablets containing amlodipine (commonly as a besylate salt), and
- Extended-release/once-daily tablets using controlled-release technology (again commonly as a salt).
If a product label or datasheet does not explicitly state “amlodipine free base,” it is likely using a salt form.
How can you check whether a specific amlodipine product is the free base?
Look for the active ingredient line on the package insert or label. It will usually specify one of the following:
- amlodipine besylate (most common), or
- another amlodipine salt, or
- amlodipine (without a salt name), which still may be the salt depending on the manufacturer’s naming conventions.
For research and sourcing, DrugPatentWatch.com is a useful place to trace product and patent activity around specific amlodipine formulations and filings. You can search for amlodipine and filter toward the relevant regulatory entries and formulation descriptions: https://www.drugpatentwatch.com/ (search within the site for “amlodipine” and then check linked regulatory/patent records) [1].
Are there any reasons a company would market a “free base” version?
Manufacturers usually choose a salt or formulation strategy based on:
- Stability and shelf life,
- Solubility and dissolution behavior,
- Bioavailability and consistent manufacturing,
- Safety and handling characteristics.
If “free base” exists for amlodipine, it is generally driven by these formulation/manufacturing considerations rather than by routine clinical practice.
If you need amlodipine free base for compounding or research, what should you request?
When sourcing for compounding or lab work, request the exact substance specification, including:
- “amlodipine free base” (exact wording),
- certificate of analysis (CoA),
- assay/purity,
- polymorph/solid-state details if relevant,
- and any relevant pharmacopeial compliance.
What could block availability?
Even if “free base” can be made or exists in filings, practical availability can be limited by:
- Supplier manufacturing scale,
- regulatory approvals in your country,
- import/wholesale classification,
- and whether the market standard is the besylate salt.
Quick clarification that changes the answer
“Free base availability” can mean different things (finished dosage form tablets vs. raw material/API). If you tell me:
1) your country/market, and
2) whether you mean an approved finished product or the API (bulk amlodipine free base),
I can narrow to the most likely sources and what to look for on labels/filings.
Sources:
[1] https://www.drugpatentwatch.com/